Mosaic ImmunoEngineering, Inc. CPMV
0.06 USD -0.08 (-56.20%)
At closeOct 30, 2026, 4:00 PM EDT
0.06 Day range 0.06
0.054 52-week range 0.89
- YTD
- -80.71%
- 1 year
- -92.84%
- Market cap
- 434.53K
- EPS (ttm)
- -0.10
- YTD return
- -80.71%
- 1-year return
- -92.84%
- Volume
- 2
- Avg volume
- 468
- Open
- 0.06
- Previous close
- 0.137
- Day's range
- 0.06 – 0.06
- 52-week range
- 0.054 – 0.89
- Earnings date
- Nov 2, 2023
2Y -0.7400 (-90.35%)
Next earnings
Nov 2, 2023
Expected Nov 2, 2023. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 19, 2024 | Sep 1, 2024 | 0.00 | -0.03 | — | — |
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | -0.04 | — | — |
| Apr 15, 2024 | Dec 1, 2023 | 0.00 | -0.04 | — | — |
| Nov 2, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 3, 2023 | Jun 1, 2023 | 0.00 | 0.00 | — | — |
| Nov 1, 2022 | Sep 1, 2022 | 0.00 | -0.02 | — | — |
News
Mosaic ImmunoEngineering (OTCMKTS:CPMV) Stock Jumps 432.8% – Here’s Why 
Mosaic ImmunoEngineering Inc. (OTCMKTS:CPMV) Short Interest Update 
Mosaic ImmunoEngineering Agrees to Acquire Clinical Necroptosis Cancer Therapy Assets from Oncotelic Therapeutics, Inc. 
Mosaic ImmunoEngineering Expands Immuno-Oncology Platform Through New Technology Licensing Agreement with the University of California San Diego 
Upcoming Presentation at the World Molecular Imaging Congress to Highlight Mosaic ImmunoEngineering's Lead Immuno-Oncology and Modular Vaccine Platform COVID-19 Vaccine Candidates 
Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology 
Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform 
Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego 
Newly Published Preclinical Data Highlight Broad Immune Activation of Mosaic ImmunoEngineering's Lead Intratumoral Immunotherapy Candidate, MIE-101 
Mosaic ImmunoEngineering Submits Application for Nasdaq Uplisting
Your note
Sign in to keep a note on CPMV — it syncs with the Stock Master app.